Heart Failure Drugs & Markets, 2018-2028 - Farxiga Will Dominate the Branded HF Market
DUBLIN, Feb. 6, 2020 /PRNewswire/ -- The "Heart Failure: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
HF is a global healthcare concern and affected patients suffer from poor quality of life and poor prognosis. Risk factors for HF include; diabetes, hypertension and obesity, all of which are on the rise in the current population. There is a large unmet need in HF for a treatment option that meets clinical end points in reduced mortality and hospitalization.
Key Highlights
-- The main driver of the HF market expansion will be the approval and
launch of the SGLT inhibitors for both HF-REF and HF-PEF.
-- Another prominent contributor to sales growth will be the approval of
the large number of pipeline therapies across the 8MM.
-- The major global barrier for the HF market will be the annual cost of
therapy for new pipeline drugs compared to the standard of care
generics, alongside the unwillingness for prescribers to add new drugs
to large therapy regimens.
-- The key market opportunities lie in addressing unmet needs through the
development of more efficacious drugs for HF patients for acute HF ,
HF-PEF and HF-mrEF.
Questions Answered
-- SGLT inhibitors will enter the market and see a significant uptake in
patient shares for the treatment of HF. However, there are high unmet
needs within the indication. What are the main unmet needs in this
market? Will the drugs under development fulfill the unmet needs of the
HF market?
-- The current late-stage HF pipeline consists of chronic therapies such as
Farxiga and Jardiance, post-acute therapies such as omecamtiv mecarbil
and Zynquista, and acute therapies such as istaroxime. Will the
late-stage drugs make a significant impact on the HF market? Which of
these drugs will have the highest peak sales at the highest CAGR, and
why?
-- We have seen a significant increase in the HF population, in terms of
diagnosed prevalence and there is an increase in the amount of patients
treated for HF-REF, HF-PEF and HF-mrEF. How will epidemiological changes
impact the growth of the future market?
Report Scope
-- Overview of HF, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and treatment guidelines.
-- Annualized HF therapeutics market revenue, annual cost of therapy and
treatment usage pattern data from 2018 and forecast for ten years to
2028.
-- Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and implications
for the HFtherapeutics market.
-- Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
late-stage pipeline drugs.
-- Analysis of the current and future market competition in the global HF
market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
The report will enable you to:
-- Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally a
list of acquisition targets included in the pipeline product company
list.
-- Develop business strategies by understanding the trends shaping and
driving the global HF therapeutics market.
-- Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the global
HF therapeutics market in future.
-- Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analysing the performance of various
competitors.
-- Identify emerging players with potentially strong product portfolios and
create effective counter-strategies to gain a competitive advantage.
-- Track drug sales in the global HF therapeutics market from 2018-2028.
-- Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Key Topics Covered
1 Table of Contents
2 Heart Failure: Executive Summary
2.1 The HF Market Will Exhibit Strong Growth Between 2018 and 2028
2.2 Label Expansions of Anti-Diabetic Drugs Will Fuel Market Growth
2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
2.4 Farxiga Will Dominate the Branded HF Market
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers/Targets of Interest
4.2 Classification or Staging Systems
4.3 Prognosis
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF
5.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF
5.4.4 Forecast Assumptions and Methods: Acute Hospitalizations
5.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF
5.4.6 Forecast Assumptions and Methods: Hospital Length of Stay
5.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
5.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF
5.4.9 Diagnosed Prevalent Cases of CHF by EF
5.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes
5.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
5.5 Epidemiological Forecast for Heart Failure (2018-2028)
5.5.1 Diagnosed Incident Cases of HF
5.5.2 Age-Specific Diagnosed Incident Cases of HF
5.5.3 Sex-Specific Diagnosed Incident Cases of HF
5.5.4 Diagnosed Incident Cases of HF by EF
5.5.5 AHF Hospitalizations
5.5.6 Hospital Length of Stay for AHF Hospitalization
5.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
5.5.8 Diagnosed Prevalent Cases of CHF
5.5.9 Diagnosed Prevalent Cases of CHF by EF
5.5.10 Age-Specific Diagnosed Prevalent Cases of CHF
5.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF
5.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
5.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class
5.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class
5.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan
6.6 China
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
Companies Mentioned
-- Eli Lilly
-- Boehringer Ingelheim International GmbH
-- Les Laboratoires Servier
-- Bayer
-- AstraZeneca
-- Bristol-Myers Squibb
-- Novartis AG
-- Zensun
-- Lexicon
-- Windtree Therapeutics
-- Daiichi Sankyo Co. Ltd.
-- China Medical System Holdings Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/gw78un
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/heart-failure-drugs--markets-2018-2028---farxiga-will-dominate-the-branded-hf-market-301000186.html
SOURCE Research and Markets
